Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 7:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 1,852 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Severe Mental Illness Clear all
Completed Phase 1 Interventional Results available

Development of Pregnenolone as a Treatment for Depression

NCT03645096
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Pregnenolone 500 mg, Pregnenolone 800 mg, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Oct 15, 2026, 7:45 AM EDT
Completed Phase 2 Interventional

Mechanistic Evaluation of Response in TRD (MERIT)

NCT04608396
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Disorder
Interventions
AXS-05, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
20
States / cities
Little Rock, Arkansas • Redlands, California • Sherman Oaks, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 15, 2026, 7:45 AM EDT
Completed Not applicable Interventional

Pilot Study in Multi-Coil Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depression

NCT01431001
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)
Device
Lead sponsor
Cervel Neurotech, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Atlanta, Georgia • Chicago, Illinois • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 15, 2026, 7:45 AM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder

NCT01052077
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
OPC-34712, Placebo, ADT
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
773 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
43
States / cities
Birmingham, Alabama • Arcadia, California • Beverly Hills, California + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Oct 15, 2026, 7:45 AM EDT
Completed Phase 2Phase 3 Interventional

Effects of Duloxetine vs. Escitalopram on Heart Rate Variability in Depression

NCT00215228
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
duloxetine vs. escitalopram
Drug
Lead sponsor
Duke University
Other
Eligibility
20 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 15, 2026, 7:45 AM EDT
Active, not recruiting Not applicable Interventional

DBS of the Lateral Habenula in Treatment-Resistant Depression

NCT01798407
View directory record Official record
Conditions
Treatment Resistant Major Depressive Disorder
Interventions
Activa Tremor Control Sys (DBS Implant), Randomized, staggered withdrawal phase
Device · Other
Lead sponsor
Wayne Goodman MD
Other
Eligibility
21 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 15, 2026, 7:45 AM EDT
Completed Phase 3 Interventional Results available

Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder

NCT01085812
View directory record Official record
Conditions
Depression, Major Depressive Disorder
Interventions
Levomilnacipran ER, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
30
States / cities
Beverly Hills, California • Encino, California • Garden Grove, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 15, 2026, 7:45 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

NCT06524830
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
VLS-01-203 BU, VLS-01-BU Placebo
Drug
Lead sponsor
atai Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
34
States / cities
Tucson, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 15, 2026, 7:45 AM EDT
Not listed Phase 1 Interventional

Ketamine for Major Depressive Disorder

NCT03721900
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SHX-001 Active low dose, Placebo, SHX-001 Active High dose
Drug
Lead sponsor
Shenox Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Gaithersburg, Maryland • Boston, Massachusetts • Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 15, 2026, 7:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans

NCT04032301
View directory record Official record
Conditions
Post-Traumatic Stress Disorders, Major Depressive Disorder
Interventions
Ketamine, Normal Saline
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 15, 2026, 7:45 AM EDT
Recruiting Not applicable Interventional

Accelerated Intermittent Theta Burst in Treatment-Naive Adolescents

NCT06523439
View directory record Official record
Conditions
Major Depressive Disorder, Depression in Adolescence, Depression, Major Depressive Episode
Interventions
MagPro X100 edition (MagVenture, Skovlunde, Denmark)
Device
Lead sponsor
University of Texas at Austin
Other
Eligibility
13 Years to 20 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 15, 2026, 7:45 AM EDT
Completed Not applicable Interventional Results available

Behavioral Activation and Medication Optimization For Improving Perioperative Mental Health In Older Adults Undergoing Oncologic Surgery

NCT05685511
View directory record Official record
Conditions
Older Adults, Anxiety, Depression, Major Surgical Resection of a Thoracic Malignancy, Major Surgical Resection of an Abdominal Malignancy
Interventions
Behavioral Activation, Medication Optimization, Usual care resources
Behavioral · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 15, 2026, 7:45 AM EDT
Terminated Phase 1 Interventional

Assessment of the Safety and Effectiveness of Cortical Stimulation in Subjects With Major Depressive Disorder

NCT00380042
View directory record Official record
Conditions
Depression, Depressive Disorder
Interventions
Cortical Stimulation, Sham
Device
Lead sponsor
Northstar Neuroscience
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Boston, Massachusetts • Pittsburgh, Pennsylvania • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 31, 2009 · Synced Oct 15, 2026, 7:45 AM EDT
Suspended No phase listed Observational Accepts healthy volunteers

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

NCT04031469
View directory record Official record
Conditions
Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder, Autism Spectrum Disorder High-Functioning, Alzheimer Disease, Alzheimer Dementia (AD), Alzheimer Dementia, Alzheimer Disease (AD), Crohn, Crohn Colitis, Crohn Disease (CD), Crohn Disease Colon, Myalgic Encephalomyelitis, ME/CFS, Myalgic Encephalomyelitis (ME), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Psoriasis, Psoriasis Annularis, Psoriasis Chronic, Chronic Urinary Tract Infection, Ulcerative Colitis (Disorder), Ulcerative Colitis (UC), Ulcerative Colitis Acute, Ulcerative Colitis Chronic, Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Constipation Chronic Idiopathic, Constipation, Celiac, Celiac Disease, Celiac Sprue, Lyme Arthritis, Lyme Borreliosis, Nervous System, Lyme Disease, Chronic, Cholesterol, Cholesterol Level, High, Cancer, Colon Cancer, Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis, Rheumatoid Arthritis (RA), Rheumatoid Arthritis - Rheumatism, Chronic Fatigue Syndrome (CFS), PARKINSON DISEASE (Disorder), Parkinson Disease, Parkinson Disease (PD), Depression, Major Depressive Disorder (MDD), Depression Disorder, Depression in Adults, Anxiety, Anxiety Disorder Generalized, Obsessive Compulsive Disorder (OCD), Obsessive Compulsive Disorder OCD, Obsessive - Compulsive Disorder, Bipolar, Bipolar 1 Disorder, Bipolar Disorder (BD), Bipolar Disorder I and II, Bipolar and Related Disorders, Migraine, Migraine Disorder, Diabetes (DM), Diabetes, Lupus, Lupus Erythematosus, Epidermolysis Bullosa (EB), Mesothelioma, Mesothelioma Malignant, IBS (Irritable Bowel Syndrome), Irritable Bowel, IBS - Irritable Bowel Syndrome, Irritable Bowel Syndrome (IBS), Eczema, Eczema Atopic Dermatitis, Acne, Myasthaenia Gravis, Gout
Interventions
There is no intervention in this study
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 15, 2026, 7:45 AM EDT
Completed Phase 2 Interventional Results available

Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant

NCT00905424
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Antidepressant + SPD489 (lisdexamfetamine dimesylate), Antidepressant + placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
15
States / cities
Newport Beach, California • San Diego, California • Bradenton, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 15, 2026, 7:45 AM EDT
Not yet recruiting No phase listed Observational

Walking With Overground Robotic Exoskeleton Device to Increase Behavioral Responsiveness in Patients With Disorders of Consciousness (WALK DOC)

NCT07709559
View directory record Official record
Conditions
Disorders of Consciousness Due to Severe Brain Injury, Disorders of Consciousness
Interventions
Overground Robotic Exoskeleton (ORE)
Device
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 15, 2026, 7:45 AM EDT
Completed Phase 2 Interventional

Magnetic Seizure Therapy (MST) for the Treatment of Major Depression

NCT00973934
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Magstim Theta, Thymatron System IV
Device
Lead sponsor
Sarah Lisanby
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
2
States / cities
Durham, North Carolina • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Oct 15, 2026, 7:45 AM EDT
Not listed Phase 4 Interventional

A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia

NCT02669030
View directory record Official record
Conditions
Depression, Major Depressive Disorder, MDD, Insomnia
Interventions
suvorexant, Placebo
Drug
Lead sponsor
Institute for Advanced Medical Research, Alpharetta, GA
Other
Eligibility
18 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Atlanta, Georgia • Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 15, 2026, 7:45 AM EDT
Completed Phase 3 Interventional Results available

Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)

NCT01569464
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
18
States / cities
Birmingham, Alabama • Jasper, Alabama • Gilbert, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2014 · Synced Oct 15, 2026, 7:45 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of IPX159 in Restless Legs Syndrome (RLS)

NCT01521663
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
IPX159, Placebo
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
38
States / cities
Brimingham, Alabama • Little Rock, Arkansas • La Jolla, California + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 15, 2026, 7:45 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression

NCT00042575
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Duloxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
9
States / cities
Trumbull, Connecticut • Lafayette, Indiana • Gaithersburg, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2006 · Synced Oct 15, 2026, 7:45 AM EDT
Completed Phase 1 Interventional

Effectiveness of a Technology Assisted Behavioral Intervention in Assisting People With Major Depressive Disorder

NCT00719979
View directory record Official record
Conditions
Depression
Interventions
Behavioral intervention (iCBT + TeleCoach), Internet-based cognitive behavioral therapy (I-CBT), Treatment as usual / Wait-list control
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
19 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 19, 2014 · Synced Oct 15, 2026, 7:45 AM EDT
Completed Not applicable Interventional

Contingency Management of Psychostimulant Abuse in the Severely Mentally Ill

NCT00809770
View directory record Official record
Conditions
Drug Abuse, Schizophrenia, Bipolar Disorder, Major Depressive Disorder
Interventions
Contingency Management, Non Contingent Control Condition
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 65 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 8, 2016 · Synced Oct 15, 2026, 7:45 AM EDT
Completed Not applicable Interventional Results available

Internet Based Cognitive Behavioral Therapy Effects on Depressive Cognitions and Brain Function

NCT01598922
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Internet Cognitive Behavioral Therapy
Behavioral
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 15, 2026, 7:45 AM EDT